RIPK1 and Sepsis: Preclinical studies with first‐generation inhibitors like Necrostatin‐1 showed survival benefits in sepsis models by suppressing necroptosis and cytokine release.[25, 26] However, their clinical utility is hindered by off‐target effects, metabolic instability, and suboptimal pharmacokinetics.[27, 28] Critically, no RIPK1 inhibitor has yet achieved clinical efficacy in sepsis‐induced lung injury, underscoring the unmet need for more selectivity and pharmacokinetically optimized agents.